California’s low-cost insulin plan is more than a year behind schedule with no clear timeline. Advocates say the delay is ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

a device that attaches to its Tempo insulin delivery pen rang, and has said it intends to being it to market in Europe this year. A similar add-on approach is being taken by Sanofi for its ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

In a major step forward, Sanofi, which signed last year an offtake ... and package advanced SoloStar insulin pens within the Kingdom. Once fully operational, the facility will have the capacity ...

Market OverviewThe Global Smart Insulin Pens Market was valued USD 102.86 Million in 2022 and is anticipated to reach a value ...

“Sanofi’s journey in Saudi Arabia has always been about ... Once fully operational, the facility is expected to produce approximately 15 million insulin pens annually, covering the needs of 500,000 ...

The FDA approved both a 3 milliliter (mL) single-patient-use prefilled pen and a 10 mL multiple-dose vial. Sanofi’s MERILOG™ is now the first insulin aspart biosimilar, and the third insulin ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... Both a 3-mL ...